Last reviewed · How we verify
Recombinant Zoster Vaccine
At a glance
| Generic name | Recombinant Zoster Vaccine |
|---|---|
| Also known as | BV211, (Shingrix® ), Shingrix, Shingrix® |
| Sponsor | Wuhan BravoVax Co., Ltd. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients (PHASE4)
- Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia (PHASE4)
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
- A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) (PHASE3)
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (PHASE1, PHASE2)
- Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
- Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation (PHASE2)
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Zoster Vaccine CI brief — competitive landscape report
- Recombinant Zoster Vaccine updates RSS · CI watch RSS
- Wuhan BravoVax Co., Ltd. portfolio CI